Literature DB >> 11751193

ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis.

M P Keane1, J A Belperio, M D Burdick, J P Lynch, M C Fishbein, R M Strieter.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and often fatal disorder. Fibroplasia and deposition of extracellular matrix are dependent, in part, on angiogenesis and vascular remodeling. We obtained open lung biopsies from patients undergoing thoracic surgery for reasons other than interstitial lung disease (control) (n = 78) and from patients with IPF (n = 91). We found that levels of epithelial neutrophil-activating peptide 78 (ENA-78) were greater from tissue specimens of IPF patients, as compared with control subjects. When ENA-78 was depleted from IPF tissue specimens, tissue-derived angiogenic activity was markedly reduced. Immunolocalization of ENA-78 demonstrated that hyperplastic Type II pneumocytes and macrophages were the predominant cellular sources of ENA-78. These findings support the notion that ENA-78 may be an important additional factor that regulates angiogenic activity in IPF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751193     DOI: 10.1164/ajrccm.164.12.2104106

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

1.  Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Vedang Londhe; Ying Ying Xue; Kewang Li; Roderick J Phillips; Robert M Strieter
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Reactive oxygen species-mediated p38 MAPK regulates carbon nanotube-induced fibrogenic and angiogenic responses.

Authors:  Neelam Azad; Anand Krishnan V Iyer; Liying Wang; Yuxin Liu; Yongju Lu; Yon Rojanasakul
Journal:  Nanotoxicology       Date:  2012-01-20       Impact factor: 5.913

3.  Neovascularization in a mouse model via stem cells derived from human fetal amniotic membranes.

Authors:  Hwi Gon Kim; Ook Hwan Choi
Journal:  Heart Vessels       Date:  2010-12-25       Impact factor: 2.037

Review 4.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

Review 5.  The role of CXC chemokines in pulmonary fibrosis.

Authors:  Robert M Strieter; Brigitte N Gomperts; Michael P Keane
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

6.  Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.

Authors:  C A Pappa; G Tsirakis; M Devetzoglou; M Zafeiri; R Vyzoukaki; A Androvitsanea; A Xekalou; K Sfiridaki; M G Alexandrakis
Journal:  Tumour Biol       Date:  2014-02-23

7.  Regulatory effect of cytokine-induced neutrophil chemoattractant, epithelial neutrophil-activating peptide 78 and pyrrolidine dithiocarbamate on pulmonary neutrophil aggregation mediated by nuclear factor-κB in lipopolysaccharide-induced acute respiratory distress syndrome mice.

Authors:  Hongman Wang; Jiping Zhao; Guansheng Xue; Junfei Wang; Jinxiang Wu; Donghui Wang; Liang Dong
Journal:  Exp Ther Med       Date:  2016-07-13       Impact factor: 2.447

Review 8.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

9.  Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF.

Authors:  Anand Krishnan V Iyer; Vani Ramesh; Carlos A Castro; Vivek Kaushik; Yogesh M Kulkarni; Clayton A Wright; Rajkumar Venkatadri; Yon Rojanasakul; Neelam Azad
Journal:  J Cell Biochem       Date:  2015-11       Impact factor: 4.429

10.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.